Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2007-07-18Clinical Trial Update: Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia [Phase 4]
This Phase 4 trial compares olanzapine with aripiprazole for schizophrenia and has completed.
-
FDA approval · 2007-07-06FDA Approved: ZYPREXA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA (olanzapine) from Eli Lilly and Company.
-
FDA approval · 2007-07-06FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
FDA Supplemental Application filed for ZYPREXA ZYDIS (olanzapine) by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2007-06-26Clinical Trial Update: Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia [Phase 2]
Phase 2 trial evaluating add-on sarcosine or D-serine for chronic schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2007-06-22Clinical Trial Update: Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia [Phase 3]
Phase 3 trial comparing intramuscular olanzapine depot to oral olanzapine and a low-dose depot in patients with schizophrenia. The study sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2007-06-13Clinical Trial Update: Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia [Phase 3]
A Phase 3 clinical trial comparing intramuscular olanzapine with intramuscular haloperidol in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2007-06-13Clinical Trial Update: Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics [Phase 4]
Phase 4 trial comparing two atypical antipsychotics for acute schizophrenia has completed, with results reported. The document provides a su…
-
CLINICAL_TRIALS trial_result · 2007-06-13Clinical Trial Update: Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating rapid-acting intramuscular olanzapine in Japanese patients with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2007-06-13Clinical Trial Update: Weight Gain Management in Patients With Schizophrenia [Phase 4]
A Phase 4 clinical trial update from Eli Lilly on weight gain management in patients with schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2007-06-13Clinical Trial Update: Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia [Phase 4]
Phase 4 clinical trial update evaluating a weight management program to mitigate weight gain in patients with schizophrenia; the study has c…
-
CLINICAL_TRIALS trial_result · 2007-06-12Clinical Trial Update: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia [Phase 3]
Phase 3 clinical trial update comparing olanzapine to placebo in adolescents with schizophrenia, sponsored by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2007-06-12Clinical Trial Update: Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia [Phase 3]
A Phase 3 trial comparing intramuscular olanzapine depot with placebo in schizophrenia has completed, sponsored by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2007-06-08Clinical Trial Update: A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia [Phase 2]
Phase 2 study evaluating rapid-acting intramuscular olanzapine for agitation in patients with schizophrenia has completed.
-
FDA approval · 2007-05-24FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone mesylate) submitted by Viatris Specialty LLC.
-
FDA approval · 2007-05-24FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS research · 2007-05-22Clinical Trial Update: AIMHI NT Relapse Prevention Trial [NA]
AIMHI NT Relapse Prevention Trial update (NCT00192582) sponsored by Menzies School of Health Research with listed conditions including schiz…
-
FDA approval · 2007-05-17FDA Approved: SEROQUEL XR — Original Application (AstraZeneca Pharmaceuticals LP)
The FDA approved the original NDA for SEROQUEL XR (quetiapine) from AstraZeneca Pharmaceuticals LP, establishing the extended-release formul…
-
FDA approval · 2007-05-04FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Patriot Pharmaceuticals LLC)
FDA approved a supplemental application for HALOPERIDOL DECANOATE submitted by Patriot Pharmaceuticals LLC. HALOPERIDOL DECANOATE is a long-…
-
CLINICAL_TRIALS trial_result · 2007-05-03Clinical Trial Update: The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia [Phase 3]
Phase 3 trial update evaluating the efficacy of escitalopram for negative symptoms in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2007-05-02Clinical Trial Update: The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial [Phase 4]
Phase 4 trial update evaluating aripiprazole with a focus on monitoring serum prolactin levels over 3 months in schizophrenia and related co…
-
FDA label_change · 2007-04-27FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVEGA (paliperidone) from Janssen Pharmaceuticals, Inc. The approval updates the drug's lab…
-
CLINICAL_TRIALS trial_result · 2007-04-23Clinical Trial Update: The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study [Phase 2]
A Phase 2 pilot study evaluating selective estrogen receptor modulators for schizophrenia and related psychotic disorders has completed.
-
CLINICAL_TRIALS trial_result · 2007-04-19Clinical Trial Update: Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study [Phase 4]
Phase 4 pilot study examining the effects of switching to aripiprazole on health and smoking parameters in patients with schizophrenia.
-
FDA approval · 2007-04-12FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal Consta (risperidone) from Janssen Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2007-03-22Clinical Trial Update: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone [Phase 2]
This Phase 2 study in schizophrenia evaluated ACP-103 in combination with haloperidol and risperidone and has completed, focusing on antipsy…